Back to Results
First PageMeta Content
Signal transduction / Hematopathology / Ruxolitinib / Janus kinase / Thrombocytosis / Myelofibrosis / Essential thrombocytosis / Polycythemia vera / Splenomegaly / Medicine / Biology / Tyrosine kinases


Incyte Corporate Fact Sheet VER[removed]
Add to Reading List

Document Date: 2014-03-20 13:16:07

Open Document

File Size: 1,92 MB

Share Result on Facebook

City

Houston / /

Company

Incyte Corporation / Novartis / Lilly / STRATEGIC PARTNERS / Hervé Hoppenot Incyte / Ovarian Cancer Incyte Corporation / Eli Lilly & Co. / Jakafi / /

Country

United States / /

/

Event

FDA Phase / /

Facility

Ovarian Cancer Incyte Corporation Quick Facts Corporate headquarters / MD Anderson Cancer Center / /

IndustryTerm

biopharmaceutical / pharmaceutical professionals / healthcare / pharmaceutical / /

MedicalCondition

polycythemia vera / blisters / headache / painful skin rash / essential thrombocythemia / aches / shortness of breath / chills / Rheumatoid arthritis / nausea / polycythemia vera myelofibrosis / primary myelofibrosis / fever / vomiting / fatigue / Polycythemia / essential thrombocythemia myelofibrosis / Infection / dizziness / inflammation / blood disorders / serious infection / myelofibrosis / high-risk myelofibrosis / /

MedicalTreatment

dialysis / /

Organization

FDA / /

Person

Srdan Verstovsek / Pamela M. Murphy / /

/

Position

President and Chief Executive Officer / VP / Investor Relations and Corporate Communications / pharmacist for more information / /

Product

INCB39110 / Jakafi® (ruxolitinib) / /

Technology

dialysis / /

URL

www.incyte.com / www.jakafi.com / /

SocialTag